Intravitreal injection of ISTH0036, an antisense oligonucleotide selectively targeting TGF-β2, indicated favorable pharmacokinetic and pharmacodynamic properties with potent and selective long tissue distribution and with down-regulation of TGF-β2 in patients with primary open angle glaucoma undergoing trabeculectomy [244]. This evidence concerns the gene TGFB2 and glaucoma.